AXEVIL Capital

Maven Clinic Stock Price, Valuation & IPO

Private company — Maven Clinic is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.

Status source: AXEVIL investment team

$17.45 per share (AXEVIL consensus estimate)

Source: AXEVIL consensus of recent secondary transactions · as of 10 November 2026

Last round valuation: $1.7B

Source: Series F, October 2024, post-money

Total raised: >$425M

Data last updated: 10 November 2026

About Maven Clinic

An online clinic for women and families offered as an employer benefit: IVF, pregnancy, pediatrics and menopause in one app with providers across 30+ specialties. Available to 28 million people; 2,300+ customers, including Amazon and Microsoft.

Maven was founded in 2014 in New York by Kate Ryder, who previously worked at the venture firm Index Ventures. It is an online clinic for women and families: OB-GYNs, fertility specialists, doulas, pediatricians and psychologists see patients by video around the clock, and its providers speak 30 languages. The employer or insurer pays, and the employee and her partner use the program for free; through Maven Wallet the employer reimburses the costs of IVF, surrogacy and adoption. Maven is available to 28 million people in 175 countries, and it has more than 2,300 customers, including Amazon, Microsoft, AT&T and L'Oréal. Among members with high-risk pregnancies, newborns are 32% less likely to end up in intensive care. Since May 2026 the company has also sold care directly to women. It has raised more than $425 million in total, at a last valuation of $1.7 billion.

  • Sector: AI Healthcare
  • Headquarters: New York, USA
  • Founded: 2014

Key highlights

  1. Blue Shield of California: 2.4 million members. In May 2022 the insurer added Maven to its maternal health program. With this, the company began selling the program through health plans in addition to employers.
  2. Oura: ovulation predictions from a ring. The partnership with the smart ring maker began in June 2025. In April 2026 Maven became the first to integrate Oura's ovulation predictions into its fertility program.
  3. Color Health: fertility preservation for cancer patients. Since February 2026 Color patients diagnosed with cancer have been referred to Maven specialists in egg and embryo freezing. The companies estimate that 80,000 young adults are diagnosed with cancer in the U.S. each year.

Frequently asked questions

How can I buy Maven Clinic stock before the IPO?

Not on a public exchange — Maven Clinic is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.

What is the Maven Clinic stock price?

A private company has no single official share price. AXEVIL's consensus estimate is $17.45 per share as of 10 November 2026. Its most recent round implied a post-money valuation of $1.7B (October 2024).

What is Maven Clinic's valuation (net worth)?

Maven Clinic's most recent funding round valued the company at $1.7B post-money (October 2024) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.

When will Maven Clinic IPO?

No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.

Is Maven Clinic publicly traded?

No. Maven Clinic is a private company and its shares are not listed on any public exchange.

Does Maven Clinic have a stock symbol?

No. Maven Clinic has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.

Similar companies

Risk disclosure

Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.

Full legal disclosures · All companies